Is Epitalon legal? FDA status, the July 2026 vote and what the evidence shows

The short version. Epitalon is not FDA approved and is not on the 503A Bulks List. An advisory committee voted for listing it for insomnia on 24 July 2026, a recommendation the FDA is not bound by. FDA staff recommended against, citing no clinical safety data, no study in people with insomnia and quality concerns.

What is Epitalon?

Epitalon is a synthetic four amino acid peptide, Ala-Glu-Asp-Gly, also sold as epithalon or AEDG peptide. The FDA briefing document prepared for the July 2026 Pharmacy Compounding Advisory Committee describes it as a synthetic analogue of epithalamin, a polypeptide extract of cattle pineal gland developed by Professor Vladimir Khavinson's group in Saint Petersburg. According to the FDA, Epitalon appears to have been first synthesised in 1999 because calf pineal gland was scarce. The FDA treats epithalamin and Epitalon as different substances, which matters, because several human studies that sellers quote were done with the extract, not with the peptide in the vial.

Epitalon also has the naming problem the FDA found across the July review. The nominators did not make clear whether they meant Epitalon free base or Epitalon acetate, which are different active ingredients, so the agency evaluated both on its own initiative. It is a common name rather than an adopted nonproprietary name, and the FDA says it has encountered multiple salts and derivatives sold under the same label. Online, the FDA found wellness clinics marketing Epitalon as "the fountain of youth" for ageing, skin, sleep, immunity and disease prevention. Those claims come from sellers, not from an approval or a completed trial.

In plain EnglishEpitalon is a tiny lab-made peptide modelled on an extract from cow pineal glands. It is sold as an anti-ageing product. In the US it is not an approved drug, and the extract it copies is a different substance.

Is Epitalon legal in 2026?

Epitalon's legal position rests on three dated facts. First, the FDA briefing states that Epitalon is not a component of any FDA approved drug, and an orphan drug designation it received for retinitis pigmentosa on 2 September 2010 was withdrawn or revoked on 6 January 2016. Second, Epitalon is not on the 503A Bulks List, and the FDA page on 503A bulk substances, current as of 14 May 2026, does not name it. Third, the FDA safety-risk page, current as of 22 April 2026, lists Epitalon among substances whose nominations were withdrawn, noting possible immunogenicity and that the agency lacks sufficient information to know whether it would cause harm. That takes Epitalon out of the interim categories, not into Category 1.

The committee vote is the fact most often misreported. On 24 July 2026 the committee voted on Epitalon for insomnia, and law firm McDermott Will & Schulte and the FDA Law Blog both reported the result as 7 in favour, 4 against and 1 abstention. RAPS, writing on the day, reported 7 to 5 with one abstention, and as of 9 October 2026 the FDA meeting page carried no minutes to settle the count. The FDA Law Blog also reported a pointed exchange over whether Epitalon is registered in Russia as a dietary supplement, which the FDA said it would look into. A page that calls Epitalon "now legal to compound" is describing a rule that does not exist yet.

In plain EnglishA committee said yes by a few votes. The FDA has not acted on it. Until it does, Epitalon is in the same legal position it was in before the vote.

Epitalon is sold as a longevity peptide. The FDA found no clinical study assessing its safety in humans and no study in people with insomnia, the one use it reviewed.

The Ozemback peptide legal status tracker carries Epitalon in the "recommended, not law" group alongside BPC-157, TB-500, KPV, MOTS-c and Semax, with the date of each fact. Epitalon was one of six peptides the committee backed across the two-day July 2026 meeting, and emideltide was the only one voted down. The tracker will change the Epitalon row on the day the FDA proposes or finalises a rule, because that is the event that would alter its legal status. For how the committee overrode its own staff across the meeting, see our analysis of the vote. To test what you know, try the approved, recommended or neither quiz.

What does the evidence for Epitalon show?

The FDA's conclusion: a lack of evidence of effectiveness for insomnia, no study in people with insomnia by any route, and no pharmacokinetic data in humans.

The FDA reviewed Epitalon for one use, insomnia, because the nominations did not carry enough information to evaluate the others: anti-ageing, longevity, telomere lengthening, skin, muscle and dementia prevention. The nominators submitted 26 articles; two were in Russian only, one could not be found, and none of the remaining 23 discussed a compounded Epitalon product. Seven of them concerned epithalamin, the extract, rather than Epitalon. Across the literature the FDA found three studies in which Epitalon was given to humans: two in night-shift workers by the sublingual route, and one using an injection beside the eye in patients with retinitis pigmentosa. None was a trial in insomnia, and none used the subcutaneous route the nominators proposed.

The only randomised, placebo-controlled study the FDA found, Ivko and colleagues in 2021, enrolled 75 healthy women aged 40 to 50 who mostly worked night shifts. Forty had low levels of a melatonin metabolite in urine; 20 of them received an AEDG peptide spray under the tongue for 20 days and 20 received saline. The authors reported that the metabolite rose 1.7-fold with the peptide and that 83% showed "positive dynamics" of general condition, against 25% on placebo. The FDA noted that blinding was not specified, the study was short and small, the method behind the 83% figure was not described, and sleep itself was never measured. A rise in a melatonin marker is not evidence that anyone slept better.

In plain EnglishThe human evidence is one small, short study in healthy women that measured a melatonin marker, plus two others that were not about sleep. The FDA concluded it does not show Epitalon works for insomnia.

What has been reported on safety

The FDA's safety conclusion is blunt: there are no clinical data to support the safety of Epitalon free base or Epitalon acetate when used in humans. Its FAERS search through 8 December 2025 returned no reports, and a search of the food and supplement complaint system through 5 December 2025 returned no cases, but compounders generally do not report adverse events, so an empty database proves little. The FDA flagged immunogenicity from aggregation and peptide impurities when injected. It also raised a mechanistic cancer concern: Epitalon has been shown to activate telomerase and lengthen telomeres in cells, and longer telomeres are generally associated with increased cancer risk. The mouse studies reporting fewer tumours used one fixed dose, female mice only and short exposure.

What is the Epitalon dosage?

There is no FDA approved dose of Epitalon, because there is no FDA approved product.

Every Epitalon dose figure you will find in the US comes from somewhere other than a US label. The FDA found clinic and seller websites stating amounts and recommending cycles, and vendors selling vials, capsules and an oral spray, several of them labelled "for research use only". The agency found no pharmacokinetic data in humans, so the record it reviewed says nothing on how the body absorbs or clears it by any route, and no pharmacy it could identify that compounds Epitalon. No outsourcing facility has reported compounding it. We report this because it is the record, and we do not publish a recommended dose, cycle or protocol for Epitalon or any other compound.

What is still unknown about Epitalon?

• Whether it does anything for sleep. No study in people with insomnia exists in the record the FDA reviewed.
• Whether it slows ageing in people. The telomere and lifespan findings come from cells and mice, mostly from one research group.
• How the body handles it. The FDA found no pharmacokinetic data in humans.
• Whether long exposure raises cancer risk. No two-year carcinogenicity study exists, and the mechanism the FDA described points in that direction.
• What is in a given product. Sellers do not say which form they sell, and the FDA found data on key quality attributes, including bacterial endotoxins, lacking in the nominations.
• Whether the FDA will follow the committee. The agency is not bound by the July 2026 vote, and no rule had been proposed as of 9 October 2026.

How should you read other pages about Epitalon?

Check whether the page treats epithalamin studies as if they were Epitalon studies; the FDA treats them as different substances, and the long-term mortality figures sellers quote come from the extract. Check whether it reports the July 2026 vote as a recommendation or as a change in the law; only the first is accurate. Check whether the telomere evidence it cites was in people or in cells and mice. Check who pays the author: nearly every site ranking for Epitalon benefits or dosage sells it, sells a consultation or links to a seller. This page carries a date at the top, 9 October 2026, so you can tell when it stops being current. Related files: Semax and TB-500, reviewed by the same committee.

The questions people actually type

Sources